CAJ | 학술논문

目的：通过本课题研究以乌司他丁单独及联合应用参麦注射液治疗急性胰腺炎，比较轻型和重症急性胰腺炎患者单独和联合用药的疗效。方法选取2010年至2013年间收治的急性胰腺炎患者80例，其中轻型40例，重症40例，随机分为两组：实验组（轻重型各20例）联合用药治疗，对照组（轻重型各20例）单独应用乌司他丁治疗。所有的资料录入Excel数据库，应用SPSS13．0统计软件，治疗前、后血尿淀粉酶、血常规和生化各指标均数用x珋±s表示，采用t检验；有效率的比较采用χ2检验， P＜0．05表示有统计学意义。结果轻型急性胰腺炎的治疗中，两组治疗前后差异无统计学意义（ P＞0．05）。重症急性胰腺炎患者治疗后血淀粉酶[实验组（128．1±73．6） mmol／L，对照组（412．7±123．3） mmol／L]，尿淀粉酶[实验组（102．2±51．3） mmoL／L，对照组（218．2±83．3） mmol／L]、血WBC [实验组（8．3±2．2）×109／L，对照组（12．6±2．4）×109／L]、谷草转氨酶[实验组（31．3±10．1） U／L，对照组（72．4±11．2） U／L]各组指标均数对比（t＝2．528、3．527、3．021、3．122，P＜0．05），实验组效果优于对照组，差异均有统计学意义（P＜0．05）。重症急性胰腺炎联合用药疗效较单独应用乌司他丁疗效好，实验组总有效率为95．0％，对照组总有效率为60．0％，差异有统计学意义（χ2＝7．03， P＝0．02）。结论对于轻型急性胰腺炎单纯应用乌司他丁即可获得满意疗效，对于急性重症胰腺炎，乌司他丁与参麦注射液联合应用可控制病情的发展、提高治愈率，有重要临床意义，值得推广。
목적：통과본과제연구이오사타정단독급연합응용삼맥주사액치료급성이선염，비교경형화중증급성이선염환자단독화연합용약적료효。방법선취2010년지2013년간수치적급성이선염환자80례，기중경형40례，중증40례，수궤분위량조：실험조（경중형각20례）연합용약치료，대조조（경중형각20례）단독응용오사타정치료。소유적자료록입Excel수거고，응용SPSS13．0통계연건，치료전、후혈뇨정분매、혈상규화생화각지표균수용x류±s표시，채용t검험；유효솔적비교채용χ2검험， P＜0．05표시유통계학의의。결과경형급성이선염적치료중，량조치료전후차이무통계학의의（ P＞0．05）。중증급성이선염환자치료후혈정분매[실험조（128．1±73．6） mmol／L，대조조（412．7±123．3） mmol／L]，뇨정분매[실험조（102．2±51．3） mmoL／L，대조조（218．2±83．3） mmol／L]、혈WBC [실험조（8．3±2．2）×109／L，대조조（12．6±2．4）×109／L]、곡초전안매[실험조（31．3±10．1） U／L，대조조（72．4±11．2） U／L]각조지표균수대비（t＝2．528、3．527、3．021、3．122，P＜0．05），실험조효과우우대조조，차이균유통계학의의（P＜0．05）。중증급성이선염연합용약료효교단독응용오사타정료효호，실험조총유효솔위95．0％，대조조총유효솔위60．0％，차이유통계학의의（χ2＝7．03， P＝0．02）。결론대우경형급성이선염단순응용오사타정즉가획득만의료효，대우급성중증이선염，오사타정여삼맥주사액연합응용가공제병정적발전、제고치유솔，유중요림상의의，치득추엄。
Objective To investigate the clinical effects of Ulinastin and Shenmai injection in treating acute pancreatitis. Methods From 2010 to 2013, 80 patients with acute pancreatitis were randomly divided two groups:experimental group (20 patients with mild acute pancreatitis, 20 patients with severe acute pancreaitis ) and control group (20 cases of mild acute pancreaitis, 20 cases of severe acute pancreaitis).The patients in the experimental group received combined therapy of Ulinastin and Shenmai injection, while patients in the control group received Ulinastin only.Clinical data were collected into EXCEL database and analyzed by using SPSS13.0 software.Measurement data including pre/post-operative biood and urinary amylase, WBC and ALT were compared between the two groups by Student's t test.The curative rate of the patients was evaluated by the chi-square test.P<0.05 was considered statistically significant. Results No significant difference was observed in patients with mild acute pancreaitis between the two groups (P>0.05). In patients with severe acute pancreaitis, however, significant difference was observed between the two groups, in blood amylase [exprerimental group(128.1 ±73.6) mmol/L vs control group(412.7 ±123.3) mmol/L], urine amylase [exprerimental group (102.2 ±51.3) mmol/L vs control group (218.2 ±83.3 ) mmol/L], WBC [exprerimental group (8.3 ±2.2) ×109/L vs control group (12.6 ±2.4) ×109/L], AST [exprerimental group (31.3 ±10.1) U/L vs control group (72.4 ±11.2) U/L] (t=2.528, 3.527, 3.021, 3.122 respectively, P﹤0.05).While the curative rate of combined therapy in treating patients with severe acute pancreatitis was 95.0% in the exprerimental group compared with 60.0% in the control group (χ2 =7.03, P =0.02 ). Conclusions For patients with mild acute pancreaitis, Ulinastin could produce satisfactory effects.However, the combination of Ulinastin and Shenmai injection could effectively control severe acute pancreatitis in early stage and increase the recovery rate.